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OBJECTIVES We examined the hypothesis that low-density lipoprotein (LDL) that is both oxidized and
glycosylated potently downregulates the expression of endothelial nitric oxide synthase III
(NOSIII) in human coronary endothelial cells.
BACKGROUND Diabetes mellitus is accompanied by both oxidation and glycosylation of LDL, but the
potential interaction of these processes or the pathophysiologic effects of these modified
lipoproteins on arteries are poorly understood.
METHODS Low-density lipoprotein was glycoxidized in vitro, and Western and Northern blot analyses
were used to investigate NOSIII expression in human coronary endothelial cells. Nitric oxide
(NO) bioactivity was represented by both basal and bradykinin-stimulated cellular cyclic
guanosine monophosphate accumulation and L-citrulline conversion from L-arginine. Nu-
clear run-on experiments were performed to study the transcription rate of nascent NOSIII
messenger ribonucleic acid (mRNA).
RESULTS Data showed a significant decrease in NOSIII expression after 24-h treatment with
glycosylated low-density lipoprotein (glycLDL) and oxidized low-density lipoprotein (ox-
LDL). Accordingly, we observed a significant dose-dependent reduction in NO bioactivity
(p  0.05 to p  0.001 vs. untreated cells, native low density lipoprotein [nLDL], glycLDL,
and oxLDL). Glyc-oxLDL did not reduce the half-life of NOSIII mRNA or significantly
enhance L-citrulline conversion. Nuclear run-on experiments showed that high doses of
glyc-oxLDL can reduce the transcription rate of nascent NOSIII mRNA (densitometric
analysis revealed a reduction of 25% [p 0.05 vs. untreated cells, nLDL, and glycLDL] after
treatment of cells with 300 g/ml glyc-oxLDL). The effects of glyc-oxLDL are not related
to the higher levels of oxidative compounds in comparison to those of oxLDL.
CONCLUSIONS These results indicate that glyc-oxLDL, per se, may influence signal transduction pathways
involving NO-mediated regulatory signals and NOSIII activity in human endothelial cells.
This phenomenon can adversely influence the evolution of clinical vascular complications,
coronary heart disease, and atherogenesis in diabetic patients. (J Am Coll Cardiol 2002;40:
1515–22) © 2002 by the American College of Cardiology Foundation
Biochemical modifications of low-density lipoprotein
(LDL) that affect its composition can greatly enhance the
injurious potential of LDL and its involvement in the
pathogenesis of various disease states. Indeed, oxidized
low-density lipoprotein (oxLDL) is prevalent in early and
advanced human atherosclerotic lesions (1–3) and has been
implicated in the cascade of events responsible for lesion
formation and plaque rupture (1–5). Cell-culture experi-
ments demonstrated that the deleterious effects of oxLDL
include activation of several transcription factors in arterial
cells (6–11) and altered bioactivity of endothelial nitric
oxide synthase III (NOSIII) (12,13). Nitric oxide (NO),
which is derived from the guanidine nitrogen atoms of
L-arginine through a reaction catalyzed by NOSIII (12), is
a major contributor to the regulation of vascular tone, and it
affects several pathways involved in atherogenesis and vas-
cular dysfunction (13). An oxLDL-induced decrease in the
expression of NOSIII might, therefore, lead to a decline in
NO bioavailability and in the vascular protective and anti-
atherogenic effects of NOSIII (13).
It is well established that proteins exposed to elevated
glucose concentration, for example, in diabetic patients, may
undergo glycosylation (14). Among these proteins, nonen-
zymatic glycosylation of LDL to form glycosylated low-
density lipoprotein (glycLDL) involves the reaction of
glucose with reactive amino groups and N-terminal amino
acid residues to form a keto-amine linkage (Nomenclature
Committee of International Union of Biochemistry 1984).
Glucose can also react nonenzymatically with the amino
groups of proteins to form advanced glycosylation end
products (AGEPs) (15). Furthermore, the Maillard reaction
(glycoxidation) involves a combination of both glycosylation
and oxidation of proteins (16). The addition of glucose to
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LDL incubated with metal ions (16–18) or oxygen radicals
(18) in vitro yields a higher oxidation than incubation of
LDL with oxidants alone. The pathophysiologic signifi-
cance of this process is underscored by in vivo and in vitro
evidence for glycoxidation of LDL in human atherosclerotic
plaques (16,19). Although AGEPs may have been previ-
ously considered to be restricted to diabetes mellitus and
aging (20), oxidation-related processes, per se, can lead to
their formation, and AGEPs have been identified in ath-
erosclerotic lesions without coexisting diabetes (21).
Molecular events promoted by oxLDL could be amplified
by coexisting glycoxidation. Indeed, in addition to facilitat-
ing atherogenesis, the glycosylation process may also affect
vascular function. Activation of the receptor for AGEPs
(21) and quenching of NO linked to defective endothelium-
dependent vasodilation in experimental diabetes (22) may
constitute a mechanism for chronic vascular dysfunction in
diabetic vasculopathy and atherosclerosis. These events,
together with glycosylation and oxidation of LDL, might
induce sustained vascular dysfunction and coronary heart
disease through alterations of NOSIII expression. Accord-
ingly, the goal of the present study was to explore the
mechanisms by which glycLDL and glyc-oxLDL modulate
NOSIII in human coronary endothelial cells.
METHODS
Preparation of human glycLDL and oxidation. Low-
density lipoprotein was isolated from the plasma of healthy
volunteers (2 mmol/l ethylenediamine-tetraacetic acid
[EDTA] and 1,000 UI/100 ml aprotinin) by ultracentrifu-
gation in a KBr gradient, as previously described (23).
Proteins were assayed by Lowry et al. (24). The glycLDL
was prepared by incubating native low-density lipoprotein
(nLDL) with 80 mmol/l glucose in sterile phosphate buffer
containing 2 mmol/l EDTA, 1,000 UI/100 ml aprotinin,
100 M deferoxamine, and 0.009% gentamicin for 10 days
at 37°C (21). We have previously shown that the extent of
glycosylation achieved by this method is typically 10% to
12%, as measured immunoenzymatically (17). The nLDL
was similarly incubated for 10 days at 37°C with sterile
buffer but without glucose, which resulted in glycosylation
of 1% to 1.5% (17). The nLDL and glycLDL (300 g/ml)
were then each incubated for 12 h at 37°C with 1 M
copper sulfate (17,23). The malondialdehyde concentration
was measured by the thiobarbituric acid-reactive substances
(TBARS) assay (17,23). Relative agarose mobility and
trinitrobenzenesulfonic acid (TNBSA) reactivity served as
markers of oxidatively modified proteins (17,23). Oxidized
forms of LDL were then incubated for 24 h with endothe-
lial cells at 37°C, under 95% air and 5% CO2 (see subse-
quent text).
To further investigate the dose-dependent contribution
of glycoxidative end products, we also prepared two
oxidation-matched forms of lipoproteins (second form of
oxLDL and glyc-oxLDL) containing similar amounts of
TBARS and TNBSA reactivity by interrupting the incuba-
tion of glycLDL with the oxidant at an earlier time point
(10 to 12 h) (Table 1).
Cell culture. Human coronary endothelial cells were cul-
tured using standard procedures, as described (6,8). The
incubation medium (delipidated Dulbecco’s Medium Es-
sential Medium) was supplemented with 10 ng/ml human
epidermal growth factor, penicillin/streptomycin, ampho-
tericin B, and glutamine (6,8).
NOSIII bioactivity measurements. The effect of different
forms of lipoproteins on NOSIII metabolism of 3H-
arginine to 3H-citrulline was determined using standard
Abbreviations and Acronyms
AGEP  advanced glycosylation end products
cDNA  complementary deoxyribonucleic acid
cGMP  cyclic guanosine monophosphate
EDTA  ethylenediamine-tetraacetic acid
EMSA  electrophoretic mobility shift assay
glycLDL  glycosylated low-density lipoprotein
LDL  low-density lipoprotein
mRNA  messenger ribonucleic acid
nLDL  native low-density lipoprotein
NO  nitric oxide
NOSIII  endothelial nitric oxide synthase III
oxLDL  oxidized low-density lipoprotein
RNA  ribonucleic acid
SRE  sterol-responsive element
TBARS  thiobarbituric acid-reactive substances
TNBSA  trinitrobenzenesulfonic acid
Table 1. Effects of Glycosylation and Oxidation on Low-Density Lipoprotein
MDA
(nmol/mg protein)
REM
(cm)
TNBS
(% Decrease)*
nLDL 2.0  0.6 (1.3–2.8) 1.2  0.2 (0.9–1.5) —
glycLDL 4.0  1.2† (2.6–5.3) 1.3  0.2 (1.0–1.6) —
oxLDL 28.9  4.2‡ (23.9–33.5) 2.3  0.3‡ (1.9–2.7) 29.6  5.6 (23.8–36.1)
glyc-oxLDL 40.4  4.1§¶ (35.1–45.3) 3.1  0.4§¶ (2.6–3.6) 42.6  4.8¶ (37.5–48.2)
oxLDL (second form) 25.4  3.3 (21.5–29.2) — 27.8  3.8 (23.6–32.5)
glyc-oxLDL (second form) 24.8  3.9 (20.5–29.4) — 25.9  4.1 (21.5–31.9)
*The decrease in TNBS reactivity in 18 h of oxLDL and glyc-oxLDL versus respective control agents in the absence of oxidant (mean  SD of 8 different experiments). †p 
0.05 vs. nLDL. ‡p  0.001 vs. nLDL. §p  0.001 vs. glycLDL. ¶p  0.05 vs. oxLDL. p  0.001 vs. respective nonoxidized control agents. The second forms of oxidized
lipoproteins were prepared after exposure of lipoproteins to oxidants for 10 to 12 h. Data are presented as the mean value  SD (intervals) of four different experiments:
nLDL  native LDL; glycLDL  glycosylated LDL; oxLDL  oxidized LDL; glyc-oxLDL  glycosylated and oxidized LDL.
MDA  malondialdehyde; REM  relative electrophoresis mobility on agarose gel (cm from baseline); TNBS  trinitrobenzenesulfonic acid.
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techniques, as described (25). Cell lysates (150 to 250 g
protein) were incubated with the reduced form of nicotin-
amide adenine dinucleotide phosphate (reduced nicotin-
amide adenine dinucleotide phosphate; 2 mM), CaCl2 (230
M), tetrahydrobiopterin (3 M), and 3H-arginine (0.2
Ci, 10 M) for 20 min at 37°C. The assay volume was
kept constant at 100 l. To determine whether glyc-oxLDL
altered NOS activity, the assay was repeated with EDTA
(1.7 mM) replacing calcium in the assay.
Western blot analysis. Whole-cell extracts were prepared
by a modification of the standard procedure of Western blot
analysis (6,8,26). Western blot analysis was performed with
antibodies (1:500) against endothelial NOSIII (N-20, Santa
Cruz, San Diego, California), with an epitope correspond-
ing to an amino acid sequence mapped at the aminotermi-
nus of NOSIII of human origin, without cross reactivity to
NOSI or NOSII. The protein content of the extract was
normalized with a polyclonal antibody against gamma-
tubulin protein (Sigma-Aldrich, Milan, Italy). Semiquanti-
tative densitometry of blots was performed using a Scan
LKB (Pharmacia-Sweden, Bromma, Sweden) (6,8,17).
Northern blot analysis. Total ribonucleic acid (RNA) was
isolated using spin columns (RNeasy, Qiagen Inc., Valencia,
California). Agarose/formaldehyde gels were loaded with 10
g RNA per lane, and RNA was resolved by electrophore-
sis. The RNA was transferred to a nylon membrane
(Hybond-N, Amersham, Piscataway, New Jersey) and
cross-linked by ultraviolet radiation. The membrane was
hybridized with radiolabeled alpha-32P deoxycytidine
triphosphate (random prime kit, Boehringer, Munich, Ger-
many), with the NOSIII fragment spanning between exon 3
and 4 (from nucleotides 1982 to 2703 of the human
complementary deoxyribonucleic acid [cDNA] sequence)
(27), and glyceraldehyde-3-phosphate dehydrogenase
(Gene Bank, National Library of Medicine/NIH) cDNA in
a hybridization solution (0.25 M Na2PO4, pH 7.2, 1 mM
EDTA, 20% sodium dodecyl sulfate). Hybridization was
performed overnight at 65°C using 2 106 cpm/ml for each
probe. To determine the effect of glyc-oxLDL on NOSIII
messenger ribonucleic acid (mRNA) half-life, actinomycin
D was used as an inhibitor of mRNA synthesis (28).
In vitro elongation of nascent RNA (run-on assay). Nu-
clei from 108 endothelial cells were prepared and in vitro
transcribed with (32P) uridine 5-triphosphate, as described
(29). The cDNA for NOSIII and beta-tubulin were used as
probes. pBluScript I (Stratagene, Cedar Creek, Texas)
plasmid deoxyribonucleic acid was used as a control agent.
Electrophoretic mobility shift assay (EMSA). A double-
stranded probe (1393 to 1374) containing the putative
sterol-responsive element (SRE) present in the NOSIII
promoter (28) was used as a probe in EMSA analysis.
Nuclear extracts (10 g) were used for the shift assay, as
described (7).
Determination of cyclic guanosine monophosphate
(cGMP). Endothelial cells (106 cells) were incubated with
0.5 mmol/l isobutyl-1-methylxanthine at the time of glyc-
oxLDL addition and incubated with the various forms of
LDL for 24 h. During the last 3 min, bradykinin (Sigma) at
a final concentration of 3 nM was added, followed by
extraction with trichloroacetic acid solution (30). The con-
tent of cGMP was measured using a specific immunoreac-
tivity kit (Amersham), according to the manufacturer’s
recommendations.
Statistical analysis. Data are expressed as the mean value
 SEM or, when specified, as the mean value  SD.
Differences among the groups were tested by one-way
analysis of variance, followed by the Bonferroni-corrected t
test (two-hypothesis test), with significance accepted at p 
0.05.
RESULTS
Effects of glycosylation and oxidation on LDL. Table 1
shows the degree of lipoprotein oxidation with or without
concurrent glycosylation. As previously demonstrated (17),
oxidative modification of lipoproteins was enhanced by
glycosylation: malondialdehyde and REM were increased
and TNBSA decreased more in glyc-oxLDL than in ox-
LDL or glycLDL alone. In parallel experiments, two forms
of oxidized lipoproteins (oxLDL and glyc-oxLDL) containing
similar amounts of oxidation compounds were compared
(Table 1); the second forms of oxLDL and glycLDL were
similar in their malondialdehyde and TNBSA reactivity.
cGMP activity. As shown in Figure 1, we detected a
marked dose-dependent reduction of cGMP levels in both
rest and bradykinin-stimulated cells after exposure to glyc-
oxLDL for 24 h. Under basal conditions (Fig. 1, upper
panel), we observed reductions of 25% and 40% in cGMP
levels at glyc-oxLDL doses of 30 g/ml (p  NS) and 100
g/ml, respectively (p  0.005 vs. untreated cells, nLDL,
glycLDL, and oxLDL), and a reduction of 67% at dose of
300 g/ml (p  0.01 vs. all other forms). The nLDL and
glycLDL did not show any effects on basal cGMP levels,
whereas both forms of oxLDL and glyc-oxLDL (at doses of
100 g/ml) induced a reduction of 30% in cGMP (p 0.01
vs. untreated cells, nLDL, and glycLDL). In bradykinin-
stimulated cells (Fig. 1, lower panel), all forms of LDL
blunted cGMP levels. The glyc-oxLDL reduced cGMP
activity by 42% and 64% at doses of 30 and 100 g/ml,
respectively (p  0.01 vs. untreated, nLDL, glycLDL, and
oxLDL), and by 82% at a dose of 300 g/ml (p  0.01 vs.
30 and 100 g/ml of glyc-oxLDL). Hence, at equivalent
doses of 100 g/ml, both forms of glyc-oxLDL induced a
more pronounced attenuation of cGMP accumulation, as
compared with either glycLDL or oxLDL.
NOSIII activity. The effects of glyc-oxLDL on NOSIII
activity were further explored using the 3H-citrulline assay.
To maximize the detectability of its effects, high-dose
glyc-oxLDL (300 g/ml) was used. However, even this
dose of glyc-oxLDL did not significantly modify the ability
of NOSIII protein to metabolize L-arginine to L-citrulline,
as compared with 100 g/ml of nLDL and oxLDL (56.5
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11.2 pmol citrulline [p  0.098 vs. nLDL], 64.6  9.4 mg
protein, and 58.7  8.9 min). In the presence of EDTA,
NOSIII activity was almost undetectable.
Western blot analysis performed on whole-protein ex-
tracts showed that the amount of NOSIII protein signifi-
cantly decreased after exposure of cells to glycLDL and
glyc-oxLDL (Fig. 2). Although both forms of glycLDL and
glyc-oxLDL decreased NOSIII protein compared with
nLDL, at similar concentrations, glyc-oxLDL decreased it
even further. Interestingly, when oxLDL and glyc-oxLDL
were matched for oxidative modifications, downregulation
of NOSIII protein was induced only by glyc-oxLDL,
indicating that this was likely related to glycosylation and
not merely due to different levels of oxidative compounds
(Fig. 2). These phenomena were consistent with the down-
regulation of NOSIII mRNA expression observed using
Northern blot analysis (Fig. 3). Densitometric analysis of
four pooled experiments showed a significant decrease in
mRNA for NOSIII induced by oxLDL, glycLDL, and
glyc-oxLDL. Longer exposure periods (48 to 96 h) did not
result in a further decrease (data not shown).
NOSIII mRNA stability. We investigated the effects of
glyc-oxLDL on the half-life of NOSIII mRNA. Cells were
cultured for 24 h in the presence or absence of 300 g/ml
glyc-oxLDL, and actinomycin D was then added to the cells
to further inhibit transcription. At different time points after
the addition of actinomycin D, total RNA was isolated and
examined by Northern blot analysis. The decay of NOSIII
mRNA from untreated cells and cells incubated with
glyc-oxLDL for 24 h was similar (Fig. 4), indicating that
even at a relatively high dose, glyc-oxLDL did not influence
the mRNA half-life. Indeed, glyceraldehyde-3-phosphate
dehydrogenase mRNA levels did not change throughout the
experiments (Fig. 4). Similarly, all remaining forms of
lipoproteins did not affect the mRNA half-life until a dose
of 1 mg/ml was used (data not shown).
Transcription rate of the NOSIII gene. To ascertain
whether glyc-oxLDL attenuated nascent NOSIII mRNA
formation, a nuclear run-on experiment was performed. As
shown in Figure 5, glyc-oxLDL dose-dependently de-
creased the rate of NOSIII gene transcription directly in the
nucleus. Densitometric analysis revealed that glyc-oxLDL
and its second form (at dose of 100 g/ml) induced a
nonsignificant reduction of 5% in NOSIII transcript and
a significant reduction of 25% at dose of 300 g/ml (p 
0.05 vs. untreated cells, nLDL, glycLDL, and both forms of
oxLDL), although neither glycLDL nor the two forms of
oxLDL significantly affected the nascent NOSIII gene
transcript (Fig. 5).
SRE. To further explore whether glyc-oxLDL interfered
with the regulatory elements present in the NOSIII pro-
moter, SRE was analyzed. The EMSA detects specific
DNA-protein complexes between nuclear extracts from
cells and the probe containing the SRE sequence. Cells were
incubated with nLDL, glycLDL, oxLDL, and glyc-oxLDL
at different concentrations, as indicated in Figure 6. The
glyc-oxLDL, but neither nLDL nor glycLDL nor oxLDL,
induced a significant reduction of the retarded band.
DISCUSSION
This study demonstrates, for the first time, that concurrent
glycosylation and oxidation of LDL induced and amplified
potent downregulation of NOSIII in human coronary
endothelial cells. We have found that exposure of cells to
glyc-oxLDL for 24 h resulted in a decrease in both NOSIII
mRNA and protein.
The oxLDL reduced NOSIII expression, decreasing its
protein and mRNA levels in endothelial cells from human
saphenous veins (29). Several stimuli, such as tumor necrosis
factor-alpha, lipopolysaccharide (30–32), and albumin-
derived AGEPs (28) also downregulate NOSIII (protein
Figure 1. (Upper) Cyclic guanosine monophosphate (cGMP) levels in
human endothelial cells after 24-h exposure to: native low-density lipopro-
tein (nLDL) (100 g/ml), glycosylated low-density lipoprotein (glcLDL)
(100 g/ml), oxidized low-density lipoprotein (oxLDL) (100 g/ml),
glc-oxLDL (30 g/ml), glc-oxLDL (100 g/ml), glc-oxLDL (300 g/
ml), glc-oxLDL (second form) (100 g/ml), and oxLDL (second form)
(100 g/ml). The 100- and 300-g/ml doses of glc-oxLDL reduced
significantly cGMP activity. *p  0.05 vs. untreated cells; $p  0.01 vs.
untreated cells, nLDL and glcLDL; #p  0.05 vs. oxLDL; **p  0.001 vs.
glc-oxLDL at 30 and 100 g/ml, second form of glc-oxLDL and second
form of ox-LDL; §p  0.0001 vs. untreated cells, nLDL and glcLDL.
(Lower) The cGMP levels in cells stimulated with bradykinin and exposed
for 24 h to the same lipoproteins as in the upper panel. *p  0.001 vs.
untreated cells; @p  0.01 vs. nLDL; ¶p  0.001 vs. nLDL and glcLDL;
**p  0.001 vs. oxLDL and glc-oxLDL at 30 g/ml and second form of
ox-LDL; §p  0.0001 vs. untreated cells, glcLDL, oxLDL, glc-oxLDL at
30 g/ml.
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and mRNA) in bovine aortic endothelial cells. The AGEPs
downregulate NOSIII without interfering with its tran-
scriptional rate (28), and the major mechanism involved
seems to be the enhanced degradation rate of NOSIII
mRNA, thereby reducing its half-life (31). Destabilization
of NOSIII mRNA by AGEP-bovine serum albumin could
result from a protein-mRNA interaction, which would
allow the degradation elements in the 3 untranslated region
to become active (33).
In contrast, the effects of glyc-oxLDL on decreasing
NOSIII mRNA do not seem to be post-transcriptional,
because experiments with actinomycin D did not show any
effect on NOSIII mRNA stability, as demonstrated previ-
ously for nLDL (33,34). However, the present study dem-
onstrates that glyc-oxLDL does interfere, at least in part,
with the rate of NOSIII gene transcription. Run-on exper-
iments (detecting the amount of nascent mRNA synthesis)
showed that high-dose glyc-oxLDL reduces the formation
of nascent RNA. We have also shown that SRE, which is
present in the 5-flanking region of human NOSIII (35),
could be involved in the regulation of NOSIII transcription.
Indeed, the EMSA experiments (detecting specific DNA-
protein complexes between cell nuclear extracts and the
probe containing the SRE) revealed a clear dose-dependent
decrease in the retarded band after 24-h exposure to
glyc-oxLDL. This decrease was obvious with 100 g/ml of
glyc-oxLDL and achieved a maximal 25% reduction at a
dose of 300 g/ml; nLDL and glycLDL at doses of 100
g/ml did not exert any effect. No significant decrease in the
retarded band was observed after exposure to either form of
oxLDL, suggesting that the SRE-protein complexes are
specifically reduced by glyc-oxLDL.
The reduction of NOSIII mRNA by glyc-oxLDL re-
quired a 24-h incubation period, which is a long lag time for
simple downregulation at the transcriptional level, due to a
reduction of the NOSIII promoter at the binding site. For
this reason, we cannot exclude the possibility that a more
complex mechanism might be involved in transcriptional
regulation of NOSIII by glyc-oxLDL in vivo. Moreover, it
is highly likely that another mechanism, such as an increase
of mRNA degradation, may play a role. Results obtained
with oxidation-matched forms of lipoproteins (oxLDL and
glyc-oxLDL, second forms) indicated that downregulation
of NOSIII protein and mRNA by glycoxidation was not
merely due to an increase in oxidative compounds.
Furthermore, we have shown that these effects of glyc-
oxLDL on NOSIII were functionally significant, because
exposure of cells to glyc-oxLDL for 24 h resulted in a
dose-dependent decrease in cGMP levels. We have also
observed that in the absence of LDL, bradykinin stimulated
cells and enhanced cGMP activity, in agreement with a
previous study (36). Both glyc-oxLDL and oxLDL reduced
the absolute levels of cGMP, but at comparable concentra-
tions, the effects of glyc-oxLDL were appreciably greater. In
addition, the conversion of 3H-arginine into 3H-citrulline,
under apparent Vmax conditions (25,37), is one of the
measures of NOSIII bioactivity. Under our experimental
conditions, glyc-oxLDL did not significantly modify the
inherent capability of NOSIII to metabolize L-arginine to
L-citrulline any more than nLDL or oxLDL. Our results are
consistent with those obtained with oxLDL in human
endothelial cells (38), but not with those obtained at high
Figure 3. Northern blot of endothelial nitric oxide synthase III (NOSIII)
in human endothelial cells. A  untreated cells; B  nLDL; C 
glycLDL; D  oxLDL; E  glyc-oxLDL; F  oxLDL (second form);
and G  glyc-oxLDL (second form). All concentrations are 100 g/ml.
GAPDH  glyceraldehyde-3-phosphate dehydrogenase; mRNA  mes-
senger ribonucleic acid. Other abbreviations as in Figure 2.
Figure 2. (Top) Western blot of endothelial nitric oxide synthase III (NOSIII) in cells exposed to the following conditions: A untreated cells; B native
low-density lipoprotein; C  glycosylated low-density lipoprotein (glycLDL); D  oxidized low-density lipoprotein (oxLDL); E  glyc-oxLDL; F 
oxLDL (second form); and G  glyc-oxLDL (second form). All concentrations are 100 g/ml. (Bottom) Densitometric analysis of endothlelial NOSIII
levels (mean  SD) representative of six separate experiments. Endothelial NOSIII was significantly decreased in C (*p  0.01 vs. B) and E (#p  0.0001
vs. B and C). Similarly, G was significantly decreased compared with F (**p  0.0004 vs. F).
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doses of hypochlorite-modified LDL in bovine aortic en-
dothelial cells (39). Taken together, the present study
indicates that at least one of the mechanisms involved in
downregulation of NOSIII by glyc-oxLDL may be a
decrease in the transcription rate due to reduced binding of
transcription factors to SRE—effects that subsequently
impact intracellular cGMP levels.
Glycation, per se, has been shown to enhance LDL
oxidation and contribute to the acceleration of atheroscle-
rosis (17,18,40–42). Similarly, the presence of high levels of
glycoxidation and AGEPs in serum and tissues, in associa-
tion with atherosclerosis, diabetes, renal failure, and aging,
has been well documented (14–16,19–22,43–46). Al-
though the concentrations of glyc-oxLDL used in the
present study are higher than those usually encountered in
the plasma of diabetic patients (1,14–16,21), much higher
concentrations of glyc-oxLDL can be found in poorly
controlled diabetic patients (47) and elderly diabetic patients
(47). Thus, we suggest that long-term exposure to relative
high-dose glyc-oxLDL (and AGEPs) can conceivably in-
duce significant effects on NOSIII activity in such patients.
Moreover, the major chemical glycoxidation products of
AGEPs (e.g., N-carboxymethyl lysine and pentosidine)
were found in human atherosclerotic lesions (19,40–42,48).
Endothelial dysfunction is an early event during atherogen-
esis (12,13), and the effects on NOSIII seen in the present
study suggest that endothelial dysfunction during diabetes
mellitus may be related to glyc-oxLDL–mediated signaling
alterations. Furthermore, vascular smooth muscle cell pro-
liferation is clearly associated with the accelerated diabetic
Figure 4. Cells treated with 3 nM of actinomycin D (to inhibit further transcription) in the absence () or presence () of glyc-oxLDL (300 g/ml) for
24 h before harvesting ribonucleic acid. A representative Northern blot hybridizated with a specific probe for NOSIII and GAPDH is shown. The relative
percentage of NOSIII signal is plotted against time. The results did not show any difference between the treatments. Each point represents the mean value
 SEM for three experiments. Abbreviations as in Figures 2 and 3.
Figure 5. In vitro elongation of nascent ribonucleic acid (run-on assay) performed in human endothelial cells exposed to following conditions: 100 g/ml
of nLDL, glycLDL, or oxLDL; glyc-oxLDL at 30, 100, and 300 g/ml; and 100 g/ml of the second forms of glyc-oxLDL and oxLDL. Densitometric
analysis revealed a 25% reduction in NOSIII transcript after treatment with 300 g/ml of glyc-oxLDL (*p  0.05 vs. all other forms). Abbreviations as
in Figures 2 and 3.
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vasculopathy. Nitric oxide mediates cytostasis of subendo-
thelial smooth muscle cells (48,49), and AGEPs may favor
cell proliferation by quenching endothelium-derived NO in
proliferative diabetic vascular lesions (39,50), playing a
significant role in their onset. Thus, glyc-oxLDL may
contribute to proliferative vasculopathy through interference
with the NO-signaling pathway. Because NOSIII is local-
ized in regions of the membrane identified as caveolae
(51,52), further studies are needed to address the possible
effects of glyc-oxLDL on caveolar rearrangements. More-
over, newly developed NO donors should be investigated in
advancing vascular diseases associated with diabetes (53).
Thus, concurrent glycosylation and oxidation of LDL
have a profound impact on downregulation of NOSIII
activity in human endothelial cells. Notably, gene transfer of
NOSIII improves relaxation of carotid arteries from diabetic
rabbits (54), supporting a physiologically significant role for
this pathway in the vascular regulation of diabetes. Al-
though cell-culture studies may indeed bear only partial
relevance to pathophysiologic mechanisms activated in vivo,
glycoxidation and NO-related cascade of events may, in
turn, influence the evolution of atherogenesis, coronary
heart disease, and other vascular complications in diabetic
patients, especially in poorly controlled and/or elderly pa-
tients.
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